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Abstract 
Background: The aim of this study was to review the available literature and define 
clinical practice guidelines for the use of laser and other light therapies for the prevention 
and treatment of oral mucositis.  
 
Methods: A systematic review was conducted by the Mucositis Study Group of the 
Multinational Association of Supportive Care in Cancer / International Society for Oral 
Oncology (MASCC/ISOO). The body of evidence for each intervention, in each cancer 
treatment setting, was assigned an evidence level. Based on the evidence level, one of the 
following three guideline determinations was possible: Recommendation, Suggestion, No 
guideline possible. 
 
Results: A recommendation was made for low level laser (wavelength at 650 nm, power 
of 40 mW, and each cm2 treated with the required time to a  tissue energy dose of 
2J//cm2) for the prevention of oral mucositis in adult patients receiving hematopoietic 
stem cell transplantation conditioned with high-dose chemotherapy with or without total 
body irradiation. A suggestion was made for low level laser (wavelength around 632.8  
nm, the power of 10-60 mW, and each cm2 treated with the required time to a  tissue 
energy dose of 2j/cm2) for the prevention of oral mucositis in patients undergoing 
radiotherapy for head and neck cancer. No guideline was possible for other light sources 
such as infra-red LED and broad band visible light therapy, due to insufficient evidence. 
 
Conclusions Best evidence available supports the use of GaAlAs at 650 nm wavelength 
at low intensity of 40 mW and each cm2 treated with the required time to a tissue energy 
dose of 2J/cm2 for the prevention of oral mucositis in HSCT patients. Additional lasers 
and other light sources were reported to be effective in similar wavelengths range and 
intensities. Well-designed research is needed to evaluate the oral mucositis prevention 
and treatment efficacy of other laser wavelengths and light therapy in other cancer 
treatment settings. 
 
 
Keywords: oral mucositis, stomatitis, laser therapy, LLLT, LED, oral complications of 
cancer therapy, mucositis prevention, mucositis treatment 
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Introduction 
 This manuscript is part of a collaborative effort of the Multinational Association 
of Supportive Care in Cancer (MASCC) mucositis study group to update the existing 
guidelines for the prevention and treatment of oral mucositis in cancer patients. The 
original and last update of the guidelines in 2004 and 2007 respectively 
1,2
 reviewed the 
various therapies for mucositis, including the use of low level laser therapy (LLLT). 
3
 
 LLLT is based on the interaction of light at low energy density, a few J/cm
2
, with 
cells and tissues without the generation of thermal effects. This type of therapy is 
believed to promote photochemical, photophysical and photobiological effects in cells 
and tissues, without causing temperature rise above 98
o
 F. It is believed that the 
biomodulation effect over cells and tissues occurs due to the absorption of the laser light 
by endogenous photoreceptors.
4
 In 1989, a review of several in vitro studies 
5
 revealed 
that primary phothoactivated receptors are components of the cellular respiratory chain. 
The activation of these receptors could lead to the stimulation or inhibition of the cellular 
metabolism, depending on the energy dose of light. Low energy doses could regulate the 
production of reactive oxygen species (ROS). It is known that the radiation wavelength 
can be beneficial to cells and tissues, 
4
 but there is uncertainty on how this happens. 
Visible light can lead to photochemical changes in the photoreceptors in the 
mitochondria, altering cell metabolism and producing a transduction effect in other cell 
components (biomodulation effect). 
5
 Others suggest that this effect is due to photo 
physical changes on the Ca++ channels in the cell membrane .
6
 
 At the time of the last MASCC/ISOO mucositis guidelines review,
3
 studies testing 
laser therapy were few. Variable protocols for preventing and treating mucositis, the large 
6 
 
variation in the wavelength used, the technique used to deliver laser to tissues, and the 
use of diverse mucositis-grading tools did not allow for conclusive results making it 
impossible to standardize a particular protocol. Although the results were encouraging, 
no recommendation for the use of the LLLT was possible. As part of a comprehensive 
update of the MASCC/ISOO clinical practice guidelines for mucositis, the aim of this 
project was to systematically review the available literature and define evidence-based 
clinical practice guidelines for the use of laser and other light therapy devices for the 
prevention and treatment of oral mucositis. 
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Methods 
 The methods used in this systematic review are described in detail in Bowen et al. 
[[ref in this issue]] and Elad et al. [[ref in this issue]]. Briefly, a literature search for 
relevant papers indexed before 31
st
 December 2010 was conducted using 
OVID/MEDLINE, with papers selected for review based on defined inclusion and 
exclusion criteria. 
 Selected papers were reviewed by two independent expert reviewers and data was 
extracted using a standard electronic form. Studies were scored for their Level of 
Evidence based on Somerfield criteria 
7
 and flaws were listed according to Hadorn 
criteria. 
8
 A well-designed study was defined as a study with no major flaws per the 
Hadorn criteria. 
8
  
 Findings from the reviewed studies were integrated into guidelines based on the 
overall Level of Evidence for laser and other light therapy agents. Guidelines were 
classified into 3 types: recommendation, suggestion, and no guideline possible. 
Guidelines were separated based on 1) the aim of the intervention (prevention or 
treatment of mucositis); 2) the treatment modality (radiotherapy, chemotherapy, chemo-
radiotherapy, or high dose conditioning therapy for hematopoietic stem cell transplant), 
and 3) the route of administration of the intervention, when applicable. 
 The list of intervention keywords used for the literature search of this section 
included oral mucositis or stomatitis AND lasers, laser, LLLT, low level laser therapy, 
light therapy, phototherapy, low-level laser, LED, light-emitting diode, diode, visible 
light, He-Ne, InGaAlP, GaAlAs, InGaAs, CO2, and infra-red. 
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Results 
 
 The literature search identified a total of 692 papers from which a total of 24 
clinical trials were included for final review. 
9-32
 The literature review process can be 
seen in Figure 1. 
 
 
 
HSCT induced oral mucositis 
A recommendation was possible for laser therapy in the wavelength around 650 
nm, the intensity of 40 mW, and each cm2 treated with the required time to a tissue 
energy dose of 2J/cm2 for the prevention of mucositis in HSCT. This guideline is based 
on the combination of one well-designed randomized clinical trial with no major flaws 
11
 
together with a series of studies reporting positive results with laser in a similar range of 
wavelength which were classified as lower level of evidence.  
The pivotal trial evaluated the efficacy of two different low level Gallium 
Aluminum Arsenide (GaAlAs) diode lasers, 650nm and 780nm wavelengths in the 
prevention of oral mucositis in Hematopoietic Stem Cell Transplantation (HSCT) patients 
conditioned with chemotherapy or chemoradiotherapy. 
11
  Patients with clinically normal 
oral mucosa received intra-oral laser irradiation in several areas of the mucosa, with 
energy densities of 2J/cm
2
. Because of the preventive nature of the study, laser treatment 
began on the first day of the conditioning and continued through day +2 post HSCT. It 
was observed that the severity of oral mucositis score in patients treated with the 650nm 
laser were reduced, compared with placebo, and the 780nm laser groups (p=0.06). Of 
importance is the fact that patients in the 650 nm group statistically significantly likely 
received total body irradiation (TBI) thus a more aggressive therapy protocol. An 
9 
 
adjusted statistical test for TBI showed that the difference in mucositis severity on day 11 
post HSCT was statistically significant (p=0.03). Laser therapy was well-tolerated and no 
adverse events developed. 
 
In contrast to the above mentioned guideline, no guideline was possible for laser 
as a treatment of oral mucositis in HSCT patients. A single study with mixed cancer 
population 
17
 was insufficient to allow for a stronger guideline.  
Two non-laser light-therapy devices were reported in the literature for the prevention of 
oral mucositis in HSCT patient population: LED and broad band visible light therapy. 
18,19
  Since it is unclear at present whether these modalities have the same mechanism as 
laser therapy, each was referred separately. As to LED, there are accumulating data 
showing that there is no difference in the interaction of a laser and a LED with the human 
tissue. 
33-37
 These studies showed positive effects in prevention and treatment of oral 
mucositis but represent initial investigations of new light technologies and with the 
available information no guideline was possible. 
 
Radiotherapy induced oral mucositis 
A suggestion was possible for the laser therapy in the prevention of oral mucositis 
in patients undergoing radiotherapy for head and neck cancer. This guideline is based on 
3 studies showing positive results with laser therapy in the wavelength of 632 nm. 21-23 
However, all three studies had major and minor flaws which did not allow for a 
recommendation. 
Radio-chemotherapy induced oral mucositis 
10 
 
No guideline was possible for laser therapy in the prevention and or treatment of 
oral mucositis in patients treated with combined protocol of radio-chemotherapy for head 
and neck cancer. Studies were inconsistent in demonstrating effectiveness of laser 
therapy. 
24-26
 In addition, major flaws in study design reduced the overall level of 
evidence to IV. 
Chemotherapy induced oral mucositis 
No guideline was possible for this category either for prevention of treatment of 
mucositis using laser therapy or LED. 
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Discussion 
 
 This systematic review confirmed that the number of clinical trials assessing the 
use of laser and other light therapies in the prevention and control of oral mucositis is 
growing. However, it is important to keep in mind that the data presented in this review 
results from the use of a variety of low level laser and other light devices that operate in 
different wavelengths and are applied to tissues using a variety of protocols. All devices 
were within the range considered to be low-level laser (10-200 mW) (Table 1). Laser 
application protocols vary greatly and, therefore, conclusions cannot be applied 
separately for each of the individual laser devices. 
 Based on the current scientific information, the panel was able to reach the 
following decision: “The panel recommends that, for centers able to support the 
necessary technology and training, LLLT be used to prevent oral mucositis, using a low 
level laser. Best evidence support the following protocol: 650nm, with the intensity of 
40mW and each cm2 treated with the required time to a tissue energy dose of 2J//cm2 to 
the oral mucosa in HCT adult population receiving high-dose CT with or without TBI. 
11
  
This represents an improvement from previous guidelines in which the use of laser 
therapy was only a suggestion and that new evidence from additional randomized trials 
was necessary before a recommendation could be made 
1,2
, reflecting the growing interest 
in the use of these devices in oral mucositis. 
 The recommendation above is supported by two Cochrane meta-analysis that 
evaluated prevention and treatment of oral mucositis with LLLT. The Cochrane 
prevention meta-analysis 
38
 found two studies 
13,15
 that were considered level III evidence 
showing 80% reduction in the incidence of severe mucositis in HSCT. However these 
12 
 
studies had major flaws by the Hadorn criteria and therefore, could not be considered for 
a recommendation by the panel. In addition, the Cochrane treatment meta-analysis 
39
 
presented two additional studies 
17,20
 with statistically significant benefits for LLLT in 
oral mucositis but had major flaws by Hadorn criteria. 
To emphasize the growing body of evidence in favor of LLLT in oral mucositis, 
several relevant late-breaking publications have been added to the laser-oral mucositis 
literature since the time we completed the literature search in December 2010. A 
systematic review with meta-analysis concluded that there is consistent evidence from 
small high-quality studies (mostly also included in the present review) that red and 
infrared LLLT can partly prevent development of cancer therapy-induced OM. LLLT 
significantly reduces pain, severity, and duration of symptoms in patients with OM. 
40
 
Additional data from a trial with near-infrared light-emitting diodes applied extraorally in 
children and adults with hematological malignancies and solid tumors treated with HSCT 
demonstrated that the technology can significantly reduce patient-reported pain. 
41
 A 
recent randomized study in patients with malignancies treated with HSCT confirmed that 
oral mucositis incidence and severity can be reduced with LLLT. 
42
 
 
Late-breaking studies showed  positive outcomes of prevention and treatment of 
oral mucositis in head and neck cancer populations being treated with radiation therapy 
43
, and in prevention of oral mucositis in head and neck cancer populations being treated 
with concurrent chemoradiation confirming that this technology seems to be effective in 
controlling the appearance and severity of oral mucositis, its associated pain, and it can 
also have beneficial effects on quality of life. 
44,45
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Indication Laser 
type  
Type of 
light 
therapy 
Wave-
length  
(nm) 
Laser setting 
(power, 
energy, time; 
or intensity,, 
energy)  
Route of 
Applicatio
n 
(Intra/ 
Extra-oral)  
 
Treatment 
Modality  
(HSCT w/wo 
TBI, CT, H&N 
RT, or mixed) 
Patient 
populatio
n 
Reference  
(author, year)  
Effectiveness Overall 
level of 
evidenc
e 
Guideline  Comments 
 
P HeNe Laser 632.8 60mW; 
1.5J/cm2, 10 
sec 
IO HSCT w TBI Adult Cowen 1997[9] Y - III II Recommendation He-Ne Laser decreases 
severity but not incidence 
of OM 
HeNe  Laser 632.8 25mW; 1J/cm2, 
40 sec 
IO HSCT w/wo TBI Adult Barasch 
1995[10] 
Y - III He-Ne Laser decreases 
severity but not incidence 
of OM 
GaAlAs  Laser 
diode 
650 / 
780 
40/60mW; 
2J/cm2, a 
IO HSCT w/wo TBI Adult Schubert 
2007[11] 
Y - II Diode 650 nm 2J / cm2 
LLLT reduces OM severity 
GaAlAs  Laser 
diode 
660 10mW 
2.5J/cm2, 10 
sec 
IO HSCT w/wo TBI Adult Jaguar 
2007[12] 
Y - III Laser increased time of 
OM appearance, reduced 
time of pain and morphine 
use 
GaAlAs  Laser 
diode 
780 60mW; 4J/cm2, 
time-NS 
IO Mixed: HSCT* & 
CT 
 
Pediatric 
 
Cruz  2007[13] N – III No evidence of benefit 
from the prophylactic use 
of low energy laser in 
patients with cancer on 
chemotherapy who 
received optimal dental 
and oral care.  
InGaAIP Laser 
diode 
660 40mW; 
4/6J/cm2, time-
NS 
IO HSCT w/woTBI Mixed Eduardo 
2009[14] 
Y – IV OM measured by WHO 
scale was maintained at 
grades I and II in 22/30 
patients, grade III in 7 and 
IV in 1, in HSCT patients 
receiving high-dose CT 
InGaAlP  Laser 
diode 
660 50mW; 4J/cm2, 
16.7 sec 
IO HSCT w/woTBI 
 
Adults 
 
Antunes 
2007[15] 
Y - III Preventive use of Laser in 
HSCT patients is a 
powerful instrument in 
reducing the incidence of 
OM 
InGaAlP 
/ 
GaAlAs  
Laser 
diode 
660 / 
780 
25mW; 
6.3J/cm2, 10 
sec 
IO Mixed: HSCT 
w/wo TBI & CT 
 
Adults 
 
Khouri 
2009[16] 
Y - III LLLT – lower frequency, 
progression, and severity 
of OM 
T GaAlAs 
 
Laser 
diode 
830 100mw; 4J/cm2, 
b 
IO Mixed: HSCTd & 
CT 
Pediatric  
 
 
Kuhn 2009[17] Y - III III No guideline 
possible 
encourage pediatric 
oncologists to use laser 
therapy as first-line option 
for children with 
chemotherapy-induced 
OM. 
P LED Light 
emitting 
diode 
670 56mW/cm2 
4J/cm2, 71 sec  
EO HSCT w/woTBI 
 
Mixed 
 
Whelan 
2002[18] 
Y – III III No guideline 
possible 
Although more studies are 
needed, LED therapy 
appears useful in the 
prevention of OM in 
pediatric HSCT patients 
P Visible 
light 
 
Visible 
light 
400-
1200 
165-
200mW/cm2 
9-18J/cm2, 
45-90 sec 
IO HSCT d 
 
Adult Elad 2011[19] Y - III III No guideline 
possible 
Broad band visible light 
therapy is safe and 
effective in the prevention 
of oral mucositis in HSCT 
patients. 
T NS  NS 100mW for 
“laser”; 50, 
250,500mW for 
“infra-red”, 2 
J/cm2, 33 sec 
IO HSCT w/wo TBI 
 
Adult Genot-
Klastersky 
2008[20] 
Y - III III No guideline 
possible 
Therapeutic laser therapy 
is beneficial for patients 
undergoing HSCT in 
delaying the development 
of OM grade 3. 
in reducing the  
             
P HeNe Laser 632.8 60mW; 2J/cm2, 
3 sec 
IO RT of H&N Adult Bensadoun 
1999[21] 
Y - III III suggestion He-Ne effective in 
preventing RT OM 
HeNe Laser 632.8 10mW; 
1.8J/cm2, 3 min 
IO RT of H&N Adult Arun Maiya 
2006[22] 
Y -III OM healing time reduced 
Effective for P & T 
HeNe Laser 632.8 10mW; 
1.8J/cm2, b 
EO & IO RT of H&N Adult Arora 2008[23] Y - III Significant reduction of 
OM grade in study group 
             
P InGaAlP  Laser 
diode 
685 35mW; 
1.1J/cm2, 32 
sec 
IO CT/RT of H&N Adult Kelner 
2007[24] 
N - IV IV No guideline 
possible 
LLLT and Chlorhexidine 
have similar effects 
InGaAlP Laser 
diode 
660 30mW, 2 J/cm2, 
time-NS 
IO CT/RT of H&N Adult Zanin 2010[25] Y - IV Improves quality of life and 
decreases incidence of 
OM in patients with H & N 
cancer treated with CT 
and RT 
NS   830 60mW; 
12J/cm2, time-
NS 
IO CT/RT of H&N  Adult Lima 2010[26] Y - IV Delayed appearance of 
OM. Similar results for 
LLLT and Aluminun 
Hydroxide 
T GaAlAs / 
InGaAlP  
Laser 
diode 
808 /  
660 
40mW; 6J/cm2, 
6 sec 
IO CT/RT of H&N Mixed Simoes 
2009[27] 
N - IV IV No guideline 
possible 
Laser applied 3/week 
maintains oral mucositis to 
grades 1 and 2. Not 
enough information to 
allow for a conclusion 
             
P GaAlAs  
 
Laser 
diode 
685 35mW; 2J/point 
70J/cm2, 54 sec 
IO CT 
 
Mixed Abramoff 
2008[28] 
Y - IV IV No guideline 
possible 
LLLT has both a 
preventive and a 
therapeutic role in those 
prone to develop OM 
NS  NS 100mW for 
“laser”; 50, 
250,500mW for 
“infra-red”, 2 
J/cm2, 33 sec 
IO CT 
 
Adult Genot-
Klastersky 
2008[20] 
Y - III Preventive laser therapy in 
beneficial in reducing the 
occurrence and intensity 
of OM in patients with 
solid tumors who have had 
previous mucositis  
T NS  830  45-50mW; 0.7-
0.8J/cm2, 10-30 
min c 
IO CT Adult Wong 2002[29] Y - IV IV No guideline 
possible 
Reduced incidence and 
severity of OM 
GaAlAs  685 35mW; 2J/point 
70J/cm2, 54 sec 
IO CT Mixed Abramoff 
2008[28] 
Y - IV pain relief and possible 
decrease in the severity of 
OM 
InGaAlP   660 / 
830 
100mW; 
2J/cm2, time-
NS 
EO CT  Pediatric 
 
Moraes 
2009[30] 
Y – IV Both 830 and 660nm 
lasers improved healing of 
oral mucositis with extra-
oral application in pediatric 
patients with established 
oral mucositis 
AsGaAl Laser 
diode 
830 250mW; , 35 
J/cm2, e 
IE CT Adult Nes 2007 Y-IV Study aimed at the 
analgesic effect only 
T LED  645±15 7.8mW; 
0.99J/cm2, 5 
min c 
IO CT Adult Corti 2006[31] Y – V V No guideline 
possible 
The median healing time 
was 1.7 and in 7 L+ 
patients, was shorter than 
in the L- group. The 
healing rate increased  
             
T NS  660  30mW; 2J/cm2, 
66 sec 
IO Mixed: RT of 
H&N & CT 
Mixed Sandoval 
2003[32] 
Y - IV   beneficial effects on the 
management of oral 
mucositis, improving the 
quality of life 
 
 
NS – not specified, P – prevention, T – treatment, IO – intra-oral, EO – extra-oral, HSCT – hematopoietic stem cell transplantation, w – with, wo – without, TBI – total body 
irradiation, CT – chemotherapy, H&N – head and neck, RT – radiotherapy, Y – yes, N – no 
 
a – the Methods refer to the formula to calculate the time for each application point (t[s]=energy [J/cm2] X surface area [cm2]/Power [W]); the surface area was measured per 
patient at baseline (numeric data are not reported in the source paper).   
b – the Methods specify “The treatment time for each application point was given by the equation t(s)=energy (J/cm2) X surface area (cm2)/Power (W); however, the surface area 
was not reported neither stated it was measured. 
c – time was specified per patient session and not per point of application. 
d – it is not specified whether conditioning regimen included TBI or not. 
e – time was not specified 
Pediatric - <17 years old 
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 Because of the variety of laser devices and the variation in individual protocols of 
laser and other light applications in oral mucositis, it is important to keep in mind that the 
results of each individual study apply exclusively to the cancer population studied, the 
wavelength of the laser device, and the settings utilized in that particular study. One 
additional issue that might play a role in the appearance and duration of oral mucositis is 
the absolute neutropenia observed in cancer populations treated with myelosuppressive 
therapies. 
46
 This confounder has not been evaluated in the majority of the trials and 
should be included in future investigations of the applicability of LLLT in oral mucositis 
prevention, treatment, and associated pain.  
 The mechanisms by which lasers promote beneficial effects in oral mucositis are 
still speculative and extrapolated from other experimental models. For instance, lasers are 
forms of coherent light emission. New technologies like LEDs and other non-coherent 
light waves can also be absorbed by tissue chromophores and promote biological effects. 
From the data available in the literature (Table 1) it seems that all effective light-therapy 
devices work in similar wavelength bands concentrating around picks in 650 nm, 780 nm 
and 830 nm. The 650 and 780 nm fall within the “red” range and the 830 nm fall within 
the “near infra-red” (NIR) range. It is uncertain to what extent the difference in the 
wavelength of the laser devices (for example 650 vs 632.8 nm) is meaningful in terms of 
light-tissue interaction, however, in terms of clinical outcomes there were differences in 
the effectiveness of certain wavelength and settings.  It should be noted, there are no 
studies assessing the effectiveness of laser or other type of light source in non-red or NIR 
range. Thus, it may be possible that additional wavelength will be effective.  
14 
 
With the advancement of the technology, the early high pricing laser emitting 
devices has been reduced considerably, making the technology readily available. 
Education and training of staff is another factor that must be considered when using 
LLLT. Most of the protocols studied require daily and long applications. However, based 
on the evidence available we predict that LLLT will be soon incorporated as a routine 
practice in the prevention and treatment of oral mucositis and its associated pain. New 
studies should focus on the determination of the most effective source of light, the setting 
of theenergy to be delivered to the tissues, and the role of other confounders like cancer 
type, cancer therapy, and extent of myelosuppression. The newly available blue LED 
bring a new potential to the management of oral mucositis and research is warranted 
based on the known effects of this light therapy in wound healing. 
47
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Figure1. Literature search: Flow of papers from initial identification through final 
selection for review. 
 
 
 
